Clinical trials: Raynaud Phenomenon
Raynaud Phenomenon Secondary to Systemic Sclerosis
Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis
This study aims to assess whether or not a single injection schedule of botulinum toxin A (BTX-A) in both hands improves Raynaud phenomenon (RP) secondary to systemic sclerosis (SSc) better than a placebo at 4, 12 and 24 weeks…
- Trial name
- BRASS (NCT03717961)
- Testing
- BOTOX® solution
- Where
- France
- Volunteers
- 91 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Raynaud Disease, Hyperemia
PORH and Response to Cold in Raynaud's Phenomenon.
The main objective of the study is to determine if implication of epoxy-eicosatriénoïc acids (EETs) and NO during cutaneous post-occlusive hyperemia differs between patients with Raynaud phenomena and healthy volunteers, by…
- Conditions
- Raynaud Disease, Hyperemia, Cold
- Trial name
- REFRAIN (NCT02183779)
- Testing
- post-occlusive hyperemia, cooling box, L-NMMA and Fluconazole dermic injection
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Systemic Sclerosis, Raynaud Phenomena
The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )
This is a 12 week double-blind randomized placebo controlled trial in which 30 patients with very early SSc, fulfilling the Very Early Diagnosis Of Systemic Sclerosis (VEDOSS) criteria (9) will be randomized in a 2:1 fashion to…
- Trial name
- NCT03059979
- Testing
- Methylprednisolone, sodium chloride
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Raynaud Phenomenon
Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Individuals with Raynaud's phenomenon often experience episodes of reduced blood flow to their fingers and toes during times of stress or cold exposure, causing significant discomfort and pain.
- Trial name
- NCT03129178
- Testing
- Concentrated beetroot juice
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Portsmouth
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The purpose of this study is to evaluate pharmacodynamics (PD) in adult subjects with a diagnosis of Raynaud's Phenomenon secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02228850
- Testing
- Alprostadil
- Where
- 4 sites in United States
- Volunteers
- 35 people
- Sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
The purpose of this study is to determine the ability of Vascana (0.9% nitroglycerin topical cream) to treat and prevent the symptoms experienced by subject's with Raynaud's Phenomenon.
- Trial name
- NCT02688270
- Testing
- Vascana (0.9% nitroglycerin cream)
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Covis Pharma S.à.r.l.
Raynaud's Phenomenon, Digital Ulcers
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Raynaud's phenomenon (RP) associated with scleroderma is a difficult problem to treat. Many patients develop ischemic digital ulcers due to severe RP that causes considerable morbidity and adversely affects the quality of life.
- Conditions
- Raynaud's Phenomenon, Digital Ulcers, Scleroderma
- Trial name
- NCT01117298
- Testing
- Tadalafil
- Where
- 4 sites in India
- Volunteers
- 66 people
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
Systemic Sclerosis, Fatigue
Apollo Device for Fatigue in Systemic Sclerosis
The purpose of this study is to learn about the effect of Apollo (a vibrating wearable about the side of an Apple Watch) on fatigue, Raynaud symptoms, depression, quality of life, and disease symptoms in patients with systemic…
- Conditions
- Systemic Sclerosis, Fatigue, Raynaud Phenomenon
- Trial name
- NCT04854850
- Testing
- Apollo
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Robyn T. Domsic, MD, MPH
Raynaud Phenomenon
Tadalafil-Delivra and Raynaud's Phenomenon
A 4-8 week observational feasibility study of the use of the use of Tadalafil-Delivra in the treatment of Reynaud's Phenomena (RP).
- Trial name
- NCT03393325
- Testing
- Observation of treatment with Tadalafil-Delivra
- Where
- 2 sites in Canada
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
- Trial name
- NCT02260557
- Testing
- Selexipag
- Where
- 16 sites in France, Germany and 1 more
- Volunteers
- 74 people
- Sponsor
- Actelion
Secondary Raynaud's Phenomenon
Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of digital ulcers related to secondary Raynaud's phenomenon associated with systemic scleroderma
- Trial name
- NCT02356809
- Testing
- Neovasculgen
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Artgen Biotech
Systemic Sclerosis, Raynaud's Phenomenon
The Effects of Exercise in Patients With Systemic Sclerosis
Systemic sclerosis (SSc) is a multisystem connective tissue disease characterised by vascular abnormalities and fibrosis, including those of the skin and can be categorised as either Limited cutaneous scleroderma or Diffuse…
- Conditions
- Systemic Sclerosis, Raynaud's Phenomenon, Quality of Life
- Trial name
- NCT03058887
- Testing
- Exercise intervention - Cycling, Exercise intervention - arm cranking
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Sheffield Hallam University
Raynaud, Scleroderma
A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Raynaud's phenomenon is thought to occur when, in response to cold or emotional stress, there is closure of the digital arteries and cutaneous arterioles leading to the clinical finding of sharp demarcated digital pallor and…
- Trial name
- NCT00498615
- Testing
- Fasudil
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Johns Hopkins University
Raynaud Phenomenon, Primary Raynaud Phenomenon
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Raynaud's phenomenon (RP) is a common vascular disorder that affects approximately 10% of the general population. RP is associated with significant morbidity that may include loss of the digits due to repeated episodes of…
- Conditions
- Raynaud Phenomenon, Primary Raynaud Phenomenon, Raynaud Disease, Raynaud Syndrome
- Trial name
- NCT03869008
- Testing
- gammaCore Sapphire
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Toledo Health Science Campus
Ischemia
Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
The purpose of this study is to investigate the effectiveness of a drug called ambrisentan, approved by the FDA for use in pulmonary hypertension (a condition where there is increased pressure in the right side of the heart) in…
- Trial name
- ambrisentan (NCT01072669)
- Testing
- ambrisentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Soumya Chatterjee
Raynaud's Disease, Scleroderma
Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's Phenomenon
The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX-503) to relieve Raynaud's symptoms and increase blood flow to the fingers.
- Conditions
- Raynaud's Disease, Scleroderma, Autoimmune Diseases
- Trial name
- NCT00419419
- Testing
- Topical AmphiMatrix with nitroglycerin (MQX-503)
- Where
- 12 sites in United States, Sweden and 1 more
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- MediQuest Therapeutics
Scleroderma, Systemic Sclerosis
Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk
Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found such as specific autoantibodies.
- Trial name
- PSSIT (NCT05098704)
- Testing
- clopidogrel treatment
- Where
- 11 sites in France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Bordeaux
Raynaud's Disease
Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon
Juvenile primary Raynaud's (ray-knows) Phenomenon is a disorder of the blood vessels in the fingers and sometimes can affect the toes, nose, or ears.
- Trial name
- NCT00048763
- Testing
- Pletal
- Where
- 18 sites in United States
- Volunteers
- 75 people
- Sponsor
- Otsuka America Pharmaceutical
Systemic Sclerosis, Raynaud Phenomenon
Rheopheresis for Raynaud's and Digital Ulcers in Systemic Sclerosis
In this feasibility study, we aim to explore therapeutic Rheopheresis (RheoP) as a novel treatment option for SSc-associated Raynaud's phenomenon and/or digital ulcers and compare it to the standard of care treatment (intravenous…
- Conditions
- Systemic Sclerosis, Raynaud Phenomenon, Digital Ulcer, Scleroderma
- Trial name
- RHEACT (NCT05204784)
- Testing
- Rheopheresis treatment, Intravenous Infusion
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Peter Korsten
Raynaud's Phenomenon
Efficacy of ORM-12741 for Prevention of Raynaud's Phenomenon
Raynaud's phenomenon (RP) is a disorder of the digital blood vessels resulting in episodic impairment of blood flow. During an attack of RP which commonly affects the hands and feet these arteries contract briefly which limits…
- Trial name
- REINO (NCT01315899)
- Testing
- ORM-12471 30mg, ORM-12471
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Orion Corporation, Orion Pharma